AI-enabled drug research reduces time and cost of drug development

Debiopharm invests in VeriSIM Life’s $15m series A round

12-Jan-2022 - Debiopharm, a Swiss biopharmaceutical company, announced their co-investment in California-based start-upVeriSIM Life’s $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence (AI). VeriSIM Life’s computational platform ...

Novartis gains exclusive rights to Debio 025, an antiviral agent as potential first-in-class hepatitis C therapy

Novartis to make upfront payment to Debiopharm Group, with Debiopharm eligible for milestones and royalties on future sales

10-Feb-2010 - Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part ...

Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas

17-Oct-2006 - The Debiopharm Group and Cambridge Antibody Technology (CAT) have entered into an exclusive worldwide licensing agreement to develop and commercialise SC-1 and all derivative products generated by the use of the SC-1 Technology. SC-1, developed by Debiopharm, is a fully human monoclonal IgM ...

Dyax Corp. and Debiopharm S.A. Restructure Development Agreement for DX-890 (Depelestat) in Pulmonary Disorders

22-Dec-2005 - Dyax Corp. and Debiopharm S.A. announced the restructuring of their long-standing development agreement for DX-890 (Depelestat), a recombinant inhibitor of human neutrophil elastase (hNE) discovered by Dyax and developed by Debiopharm, for the treatment of pulmonary disorders. Under the terms of ...

Debiovision inc, formerly H3 Pharma, a speciality pharmaceutical developer joins the Debio companies

19-Sep-2005 - Debiopharm S.A. announced the integration of its fully owned affiliate Debiovision, formerly known as H3 Pharma, a Quebec-based company focusing on the development of specialty pharmaceuticals into the Debio Group, following the purchase of all the outstanding shares of H3 Pharma in May 2005. ...